Tacrolimus systemic exposure

Tacrolimus systemic exposure refers to the total amount of the immunosuppressant drug tacrolimus present in a patient's systemic circulation over a specific dosing interval. It is not a biological target, such as a receptor or enzyme, but a clinical pharmacokinetic metric used to guide dosing in transplant recipients (StatPearls, NBK544318). Tacrolimus itself functions by binding to the immunophilin FKBP12 to form a complex that inhibits calcineurin, thereby blocking T-cell activation and preventing organ rejection (PubMed, 15831052). Because tacrolimus has a narrow therapeutic index, maintaining precise systemic exposure is vital; excessive exposure is linked to severe toxicities like nephrotoxicity and neurotoxicity, while inadequate exposure increases the risk of allograft rejection (PubMed, 25866186). Exposure is most commonly assessed in clinical practice via trough blood concentrations (C0) or the area under the concentration-time curve (AUC). Significant inter-individual variability in exposure occurs due to factors such as genetic polymorphisms in CYP3A4/5 and drug-drug interactions, making therapeutic drug monitoring (TDM) a standard of care for patients on this medication.

Other names

Tacrolimus blood levelsTacrolimus pharmacokineticsTacrolimus AUCTacrolimus trough concentrationTacrolimus C0

Not applicable; this is a pharmacokinetic parameter representing drug concentration over time rather than a biological target.